Yes, I saw what you are planning to do. Pretty smart.
But while shareholders either move on or wait, some things remain in motion.
Our cash burn continues to smolder.
Trials of Big Pharma mAbs continue to progress.
I would have to assume that our contingent sales and reserved manufacturing capacity evaporate.
Our CMC footing is jeopardized, or lost.
Discovery moves closer as to a definitive determination of lenzilumab's efficacy in our preferred patient population, I hope. I'm not sure that's the case if we really only have 200 - 250 patients enrolled. And hospitals can't spare the resources for clinical trial testing.
But unlike any of these other take-down targets, we have the silver bullet of the NIH trial. We have to hope that it doesn't prove too little, to late, or biased.
Even seeking an investigation by the Inspector General is unlikely if the FDA claims they are not able to verify trial results that have not been peer reviewed, unless a peer review is really not required.
Market Data 
Markets 
AI
